Detalhe da pesquisa
1.
cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.
Biotechnol Bioeng
; 115(4): 885-899, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29150937
2.
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
J Infect Dis
; 215(1): 95-104, 2017 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28077588
3.
Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials.
Vaccines (Basel)
; 10(10)2022 Sep 21.
Artigo
Inglês
| MEDLINE | ID: mdl-36298451
4.
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.
EBioMedicine
; 82: 104203, 2022 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-35915046
5.
Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors.
Hum Vaccin
; 7(6): 639-45, 2011 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-21508675
6.
Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.
Lancet HIV
; 6(4): e230-e239, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30885692
7.
Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine.
Vaccine
; 37(44): 6696-6706, 2019 10 16.
Artigo
Inglês
| MEDLINE | ID: mdl-31548012
8.
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
PLoS One
; 10(5): e0125954, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-25961283
9.
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.
PLoS One
; 8(2): e55831, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-23418465
10.
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
Clin Vaccine Immunol
; 20(3): 397-408, 2013 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-23345581
11.
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
PLoS One
; 7(8): e41936, 2012.
Artigo
Inglês
| MEDLINE | ID: mdl-22870265
12.
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.
PLoS One
; 7(9): e45840, 2012.
Artigo
Inglês
| MEDLINE | ID: mdl-23049876
13.
Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.
PLoS One
; 5(1): e8617, 2010 Jan 25.
Artigo
Inglês
| MEDLINE | ID: mdl-20111582
14.
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
PLoS One
; 5(1): e8816, 2010 Jan 25.
Artigo
Inglês
| MEDLINE | ID: mdl-20111599
15.
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
AIDS Res Hum Retroviruses
; 25(11): 1107-16, 2009 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-19943789